Loading patent…
AssigneeCuradigm SAS
InventorsAgnes Pottier, Matthieu Germain, Laurence Poul, Marion Paolini, Marie-Edith Meyre
Estimating the term…
The present disclosure generally relates to the field of medicine. The present invention more specifically relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle comprising, or consisting in, at least one natural compound which is an inhibitor of a human CYP enzyme, the longest dimension of said nanoparticle being of at least 4 nm and less than 100 nm, and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the combination of the at least one biocompatible nanoparticle and of the at least one compound of interest potentiates the at least one compound of interest's bioavailability. The at least one biocompatible nanoparticle is to be administered to the subject separately from the at least one compound of interest (preferably before), typically with an interval of between at least about 5 minutes (preferably more than about 5 minutes) and about 72 hours.
A therapeutic or prophylactic method comprising a step of administering at least one pharmaceutical compound to a subject in need thereof and a distinct step of administering at least one biocompatible nanoparticle to said subject, wherein the at least one biocompatible nanoparticle comprises bergamottin, 6′,7′-dihydroxybergamottin (DHB) or a mixture thereof, the longest dimension of said at least one biocompatible nanoparticle is at least 4 nm and less than 100 nm, the at least one biocompatible nanoparticle is not used as the therapeutic or prophylactic compound, wherein the at least one pharmaceutical compound is a substrate of the human CYP3A4 and/or CYP2B6 enzymes, and wherein said at least one biocompatible nanoparticle is administered separately to the subject between 5 minutes and about 72 hours before the at least one pharmaceutical compound, the at least one biocompatible nanoparticle and the at least one pharmaceutical compound being both administered to the subject through an intravenous (IV) injection route.
A therapeutic or prophylactic method comprising a step of administering at least one pharmaceutical compound to a subject in need thereof and a distinct step of administering at least one biocompatible nanoparticle to said subject, wherein the at least one biocompatible nanoparticle comprises bergamottin, 6′,7′-dihydroxybergamottin (DHB) or a mixture thereof, the longest dimension of said at least one biocompatible nanoparticle is at least 4 nm and less than 100 nm, the at least one biocompatible nanoparticle is not used as the therapeutic or prophylactic compound, wherein the least one pharmaceutical compound is a substrate of the human CYP3A4 and/or CYP2B6 enzymes, and wherein said at least one biocompatible nanoparticle is administered separately to the subject between 5 minutes and about 72 hours before the at least one pharmaceutical compound, the at least one biocompatible nanoparticle and the at least one pharmaceutical compound being both administered to the subject through an intravenous (IV) injection route, and wherein the method further comprises a step of administering a second biocompatible nanoparticle comprising at least one natural compound which is an inhibitor of a human CYP enzyme, the longest dimension of the second biocompatible nanoparticle being of at least 4 nm and less than 100 nm, and wherein the at least one (first) and/or second biocompatible nanoparticle(s) comprise(s) an agent enhancing nanoparticle(s)′ recognition by enterocytes and/or by hepatocytes.
Dependencies are inferred from the claim text.